
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a United States-based company in the Healthcare sector with a market capitalisation of $6.1B. Its FinScore is 61/100; its highest-scoring layer is Momentum (80) and its lowest is Value (32). The shares trade at 31.0x trailing earnings and are up 61% year to date.
Share price performance
About Ligand Pharmaceuticals Incorporated
www.ligand.comLigand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- HQ
- United States
- Fiscal year-end
- December
- Trading currency
- USD
- Reporting currency
- USD
- Fundamentals updated
- 76 days ago
- Market cap
- $6.1B
- Shares outstanding
- 19.9M
- P/E (TTM)
- 31.0x
- Beta (issuer)
- 1.01
- Revenue (latest FY)
- $268.1M
Revenue breakdown
Revenue split not available
FinScore
As of 2026-10-21Snapshot
Ownership
As of 2026-06-30Sign up or log in to see Analysis
Analysis for Ligand Pharmaceuticals Incorporated is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Financials
Financials for Ligand Pharmaceuticals Incorporated is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Estimates
Estimates for Ligand Pharmaceuticals Incorporated is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Peers
Peers for Ligand Pharmaceuticals Incorporated is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Valuation
Valuation for Ligand Pharmaceuticals Incorporated is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see News
News for Ligand Pharmaceuticals Incorporated is available to Finryse members. The Overview stays open to everyone; creating an account is free.